Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
679
mi
from 43215
Bellevue, NE
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
679
mi
from 43215
Bellevue, NE
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
1670
mi
from 43215
Calgary,
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
1670
mi
from 43215
Calgary,
Click here to add this to my saved trials
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children
Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children
Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
South End Community Health Center
642
mi
from 43215
Boston, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
South End Community Health Center
642
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Dorchester House Multi-Service Center
642
mi
from 43215
Boston, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Dorchester House Multi-Service Center
642
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Codman Square Health Center
641
mi
from 43215
Boston, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Codman Square Health Center
641
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Upham's Corner Health Center
642
mi
from 43215
Dorchester, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Upham's Corner Health Center
642
mi
from 43215
Dorchester, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Mattapan Community Health Center
640
mi
from 43215
Mattapan, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Mattapan Community Health Center
640
mi
from 43215
Mattapan, MA
Click here to add this to my saved trials
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated:  12/31/1969
Greater Roslindale Medical and Dental Center
638
mi
from 43215
Roslindale, MA
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Reducing Socioeconomic Disparities in Health at Pediatric Visits
Status: Enrolling
Updated: 12/31/1969
Greater Roslindale Medical and Dental Center
638
mi
from 43215
Roslindale, MA
Click here to add this to my saved trials
Effect of Fasting on the Asthma Inflammasome
Pilot Study to Evaluate the Effect of Fasting on the Asthma Inflammasome
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Effect of Fasting on the Asthma Inflammasome
Pilot Study to Evaluate the Effect of Fasting on the Asthma Inflammasome
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke
Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke
Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
WCCT Global, LLC /ID# 162380
1964
mi
from 43215
Costa Mesa, CA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
WCCT Global, LLC /ID# 162380
1964
mi
from 43215
Costa Mesa, CA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Sean N. Parker Center for Allergy and Asthma Research /ID# 162403
2086
mi
from 43215
Mountain View, CA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Sean N. Parker Center for Allergy and Asthma Research /ID# 162403
2086
mi
from 43215
Mountain View, CA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
IMMUNOe Research Centers /ID# 162381
1158
mi
from 43215
Centennial, CO
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
IMMUNOe Research Centers /ID# 162381
1158
mi
from 43215
Centennial, CO
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Yale New Haven Hospital /ID# 162378
536
mi
from 43215
New Haven, CT
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Yale New Haven Hospital /ID# 162378
536
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Trials of Florida Inc /ID# 162393
828
mi
from 43215
Tampa, FL
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Trials of Florida Inc /ID# 162393
828
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Northwestern Memorial Hospital /ID# 162400
274
mi
from 43215
Chicago, IL
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Northwestern Memorial Hospital /ID# 162400
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Asthma & Allergy Center /ID# 162404
347
mi
from 43215
Baltimore, MD
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Asthma & Allergy Center /ID# 162404
347
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Detroit Clinical Research Center, PC /ID# 162379
177
mi
from 43215
Farmington Hills, MI
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Detroit Clinical Research Center, PC /ID# 162379
177
mi
from 43215
Farmington Hills, MI
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
VA Western New York Healthcare System /ID# 162398
300
mi
from 43215
Buffalo, NY
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
VA Western New York Healthcare System /ID# 162398
300
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
American Health Research /ID# 162401
349
mi
from 43215
Charlotte, NC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
American Health Research /ID# 162401
349
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Health Care, P.A. /ID# 162405
467
mi
from 43215
New Bern, NC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Health Care, P.A. /ID# 162405
467
mi
from 43215
New Bern, NC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Wake Forest University School /ID# 162395
305
mi
from 43215
Winston-Salem, NC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Wake Forest University School /ID# 162395
305
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Solutions /ID# 162399
434
mi
from 43215
Middleburg Heights, OH
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Solutions /ID# 162399
434
mi
from 43215
Middleburg Heights, OH
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Temple University Hospital /ID# 162397
416
mi
from 43215
Philadelphia, PA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Temple University Hospital /ID# 162397
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center /ID# 162385
164
mi
from 43215
Pittsburgh, PA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center /ID# 162385
164
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Research Protocol Management Specialist /ID# 162377
163
mi
from 43215
Pittsburgh, PA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Research Protocol Management Specialist /ID# 162377
163
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
MedTrial /ID# 162382
424
mi
from 43215
Columbia, SC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
MedTrial /ID# 162382
424
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Upstate Pharmaceutical Research /ID# 162383
354
mi
from 43215
Greenville, SC
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Upstate Pharmaceutical Research /ID# 162383
354
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Respiratory and Sleep Disorders Specialists /ID# 162394
973
mi
from 43215
The Woodlands, TX
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Respiratory and Sleep Disorders Specialists /ID# 162394
973
mi
from 43215
The Woodlands, TX
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
The University of Texas Health Science Center at Tyler /ID# 162384
854
mi
from 43215
Tyler, TX
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
The University of Texas Health Science Center at Tyler /ID# 162384
854
mi
from 43215
Tyler, TX
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
O&O Alpan LLC /ID# 162402
313
mi
from 43215
Fairfax, VA
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
O&O Alpan LLC /ID# 162402
313
mi
from 43215
Fairfax, VA
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
ULB Erasme /ID# 162320
4049
mi
from 43215
Brussels,
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
ULB Erasme /ID# 162320
4049
mi
from 43215
Brussels,
Click here to add this to my saved trials
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine /ID# 162396
397
mi
from 43215
Saint Louis, MO
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine /ID# 162396
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement
Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement
Status: Enrolling
Updated:  12/31/1969
University of North Carolin at Chapel Hill
278
mi
from 43215
Chapel Hill, NC
Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement
Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement
Status: Enrolling
Updated: 12/31/1969
University of North Carolin at Chapel Hill
278
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma
Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
643
mi
from 43215
Boston, MA
Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma
Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
492
mi
from 43215
Birmingham, AL
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 13194
757
mi
from 43215
Glendale, AR
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 13194
757
mi
from 43215
Glendale, AR
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10173
1980
mi
from 43215
Bakersfield, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10173
1980
mi
from 43215
Bakersfield, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1969
mi
from 43215
Huntington Beach, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1969
mi
from 43215
Huntington Beach, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10147
1977
mi
from 43215
Long Beach, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10147
1977
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 11110
2090
mi
from 43215
Napa, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 11110
2090
mi
from 43215
Napa, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10106
2044
mi
from 43215
Stockton, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10106
2044
mi
from 43215
Stockton, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10129
2086
mi
from 43215
Walnut Creek, CA
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10129
2086
mi
from 43215
Walnut Creek, CA
Click here to add this to my saved trials
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10133
1162
mi
from 43215
Denver, CO
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10133
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials